News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Oct 14, 2019
    Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks | Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-approved PF708 product for therapeutic equivalence

    SAN DIEGO, October 14, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study...

  • Oct 11, 2019
    New Exclusive Commercialization Agreements in South Korea, Canada, and Israel | Submission of Marketing Authorization Application for PF708 in Saudi Arabia | Potential approval of PF708 in the EU as early as the second half of 2020

    SAN DIEGO, October [11], 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea...

  • Oct 7, 2019
    Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval. Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019

    SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for PF708...

  • Sep 16, 2019

    SAN DIEGO, September 16, 2019—Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Sep 10, 2019

    SAN DIEGO, September 10, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Sep 5, 2019

    SAN DIEGO, September 5, 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz...

  • Sep 4, 2019

    SAN DIEGO, September 5th, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Aug 8, 2019

    SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Aug 8, 2019
    NDA for PF708 reached the FDA mid-cycle review milestone in May | Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study | Agreement with Arcellx Leverages Pfēnex Expression Technology® platform

    SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

  • Aug 1, 2019
    First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform | Second sparX program initiated by Arcellx

    SAN DIEGO, August 1, 2019 —Pfenex Inc. (NYSE American: PFNX) and Arcellx, Inc. today announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfe

Show 5102550100 per page